Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2025-12-24 @ 9:09 PM
NCT ID:
NCT02925104
Eligibility Criteria:
Inclusion Criteria:
* cMET dysregulated advanced solid tumor
* At least one measurable lesion as defined by RECIST 1.1
* Recovered from all toxicities related to prior anti-cancer therapies to grade ≤ 1
* Adequate organ function
* ECOG performance status (PS) ≤ 1
Exclusion Criteria:
* Prior treatment with crizotinib or any other cMET or HGF inhibitor
* Known hypersensitivity to any of the excipients of INC280
* Symptomatic central nervous system (CNS) metastases who are neurologically unstable
* Presence or history of a malignant disease other than the study related cancer
* Clinically significant, uncontrolled heart diseases
* Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities
* Major surgery within 4 weeks prior to starting INC280
* Impairment of GI function
* Patients receiving unstable or increasing doses of corticosteroids
* Patients receiving treatment with any enzyme-inducing anticonvulsant
* Pregnant or nursing (lactating) women Other protocol-related inclusion/exclusion criteria may apply
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02925104
Study Brief:
Protocol Section:
NCT02925104